BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 19, 2006
 |  BioCentury  |  Product Development

Showcasing new diabetes targets

While much of the attention at last week’s American Diabetes Association meeting was focused on late-stage products targeting DPP-4 and GLP-1, companies also presented early data on new targets, including adiponectin receptor 2 and eukaryotic translation initiation factor 4E binding protein 2 from Isis Pharmaceuticals Inc. and connective tissue growth factor from Fibrogen Inc.

ISIS’s data from its antisense pipeline included a duo of gene targets for diabetes: adiponectin receptor 2 (AdipoR2), a receptor for adiponectin that was recently cloned, and eukaryotic translation initiation factor 4E (elF-4E) binding protein 2.

Adiponectin is an adipokine involved in lipid and glucose metabolism, energy homeostasis and inflammatory pathways. Genetic variations in both AdipoR2 and another recently cloned receptor, AdipoR1, are associated with insulin resistance and/or Type II diabetes.

AdipoR2 knockout mice given a high-fat diet had better overall metabolic...

Read the full 687 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >